Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 44 entries
Sorted by: Best Match Show Resources per page
Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France.

Journal of cardiology

Allou A, Baschet L, Sabourin C, Montalscot G, Lorgis L, Iriart X.
PMID: 34772575
J Cardiol. 2021 Nov 10; doi: 10.1016/j.jjcc.2021.10.009. Epub 2021 Nov 10.

BACKGROUND: A patent foramen ovale (PFO) is formed when the ovale foramen does not close spontaneously or re-opens leaving the right and left atrium connected. The present study was conducted to analyze the cost-effectiveness of PFO closure with Amplatzer...

Cite
Allou A, Baschet L, Sabourin C, et al. Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France. J Cardiol. 2021;doi: 10.1016/j.jjcc.2021.10.009.
Allou, A., Baschet, L., Sabourin, C., Montalscot, G., Lorgis, L., & Iriart, X. (2021). Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France. Journal of cardiology, . https://doi.org/10.1016/j.jjcc.2021.10.009
Allou, Amel, et al. "Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France." Journal of cardiology vol. (2021). doi: https://doi.org/10.1016/j.jjcc.2021.10.009
Allou A, Baschet L, Sabourin C, Montalscot G, Lorgis L, Iriart X. Cost-effectiveness analysis of patent foramen ovale closure with Amplatzer plus medical therapy compared to medical therapy in patients with a history of stroke in France. J Cardiol. 2021 Nov 10; doi: 10.1016/j.jjcc.2021.10.009. Epub 2021 Nov 10. PMID: 34772575.
Copy Download .nbib Format: NLM
Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial.

JAMA cardiology

Farhan S, Vogel B, Montalescot G, Barthelemy O, Zeymer U, Desch S, de Waha-Thiele S, Maier LS, Sandri M, Akin I, Fuernau G, Ouarrak T, Hauguel-Moreau M, Schneider S, Thiele H, Huber K.
PMID: 32845312
JAMA Cardiol. 2020 Dec 01;5(12):1329-1337. doi: 10.1001/jamacardio.2020.3377.

IMPORTANCE: Myocardial infarction with a culprit lesion located in the left main or proximal left anterior descending artery compared with other coronary segments is associated with more myocardium at risk and worse clinical outcomes.OBJECTIVE: To evaluate the association of...

Cite
Farhan S, Vogel B, Montalescot G, et al. Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2020;5(12):1329-1337doi: 10.1001/jamacardio.2020.3377.
Farhan, S., Vogel, B., Montalescot, G., Barthelemy, O., Zeymer, U., Desch, S., de Waha-Thiele, S., Maier, L. S., Sandri, M., Akin, I., Fuernau, G., Ouarrak, T., Hauguel-Moreau, M., Schneider, S., Thiele, H., & Huber, K. (2020). Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA cardiology, 5(12), 1329-1337. https://doi.org/10.1001/jamacardio.2020.3377
Farhan, Serdar, et al. "Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial." JAMA cardiology vol. 5,12 (2020): 1329-1337. doi: https://doi.org/10.1001/jamacardio.2020.3377
Farhan S, Vogel B, Montalescot G, Barthelemy O, Zeymer U, Desch S, de Waha-Thiele S, Maier LS, Sandri M, Akin I, Fuernau G, Ouarrak T, Hauguel-Moreau M, Schneider S, Thiele H, Huber K. Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2020 Dec 01;5(12):1329-1337. doi: 10.1001/jamacardio.2020.3377. PMID: 32845312; PMCID: PMC7450400.
Copy Download .nbib Format: NLM
Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of clinical medicine

Guedeney P, Mesnier J, Sorrentino S, Abcha F, Zeitouni M, Lattuca B, Silvain J, De Rosa S, Indolfi C, Collet JP, Kerneis M, Montalescot G.
PMID: 32138287
J Clin Med. 2020 Mar 03;9(3). doi: 10.3390/jcm9030680.

The respective ischemic and bleeding risks of early aspirin discontinuation following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) remain uncertain. We performed a prospero-registered review of randomized controlled trials (RCTs) comparing a P2Y

Cite
Guedeney P, Mesnier J, Sorrentino S, et al. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2020;9(3)doi: 10.3390/jcm9030680.
Guedeney, P., Mesnier, J., Sorrentino, S., Abcha, F., Zeitouni, M., Lattuca, B., Silvain, J., De Rosa, S., Indolfi, C., Collet, J. P., Kerneis, M., & Montalescot, G. (2020). Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of clinical medicine, 9(3), . https://doi.org/10.3390/jcm9030680
Guedeney, Paul, et al. "Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Journal of clinical medicine vol. 9,3 (2020). doi: https://doi.org/10.3390/jcm9030680
Guedeney P, Mesnier J, Sorrentino S, Abcha F, Zeitouni M, Lattuca B, Silvain J, De Rosa S, Indolfi C, Collet JP, Kerneis M, Montalescot G. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2020 Mar 03;9(3). doi: 10.3390/jcm9030680. PMID: 32138287; PMCID: PMC7141190.
Copy Download .nbib Format: NLM
Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult.

JACC. Case reports

Zendjebil S, Zeitouni M, Batonga M, El Bèze N, Guedeney P, Collet JP, Choussat R, Silvain J, Montalescot G.
PMID: 32835271
JACC Case Rep. 2020 Jul 15;2(9):1297-1301. doi: 10.1016/j.jaccas.2020.06.002. Epub 2020 Jun 09.

A 42-year-old man was admitted for an ST-segment elevation myocardial infarction revealing an acute thrombosis of the left anterior descending and right coronary arteries. Following this acute multivessel coronary occlusion in a young individual at low cardiovascular risk, he...

Cite
Zendjebil S, Zeitouni M, Batonga M, et al. Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult. JACC Case Rep. 2020;2(9):1297-1301doi: 10.1016/j.jaccas.2020.06.002.
Zendjebil, S., Zeitouni, M., Batonga, M., El Bèze, N., Guedeney, P., Collet, J. P., Choussat, R., Silvain, J., & Montalescot, G. (2020). Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult. JACC. Case reports, 2(9), 1297-1301. https://doi.org/10.1016/j.jaccas.2020.06.002
Zendjebil, Sandra, et al. "Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult." JACC. Case reports vol. 2,9 (2020): 1297-1301. doi: https://doi.org/10.1016/j.jaccas.2020.06.002
Zendjebil S, Zeitouni M, Batonga M, El Bèze N, Guedeney P, Collet JP, Choussat R, Silvain J, Montalescot G. Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult. JACC Case Rep. 2020 Jul 15;2(9):1297-1301. doi: 10.1016/j.jaccas.2020.06.002. Epub 2020 Jun 09. PMID: 32835271; PMCID: PMC7280128.
Copy Download .nbib Format: NLM
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.

Journal of the American Heart Association

Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, Špinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP.
PMID: 34423649
J Am Heart Assoc. 2021 Sep 07;10(17):e020446. doi: 10.1161/JAHA.120.020446. Epub 2021 Aug 21.

Background Coronary stent type and risk of stent thrombosis remain important factors affecting recommended duration of dual antiplatelet therapy. We investigated the efficacy and safety of long-term ticagrelor in patients with prior coronary stenting enrolled in the PEGASUS-TIMI 54...

Cite
Bergmark BA, Bhatt DL, Steg PG, et al. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2021;10(17):e020446doi: 10.1161/JAHA.120.020446.
Bergmark, B. A., Bhatt, D. L., Steg, P. G., Budaj, A., Storey, R. F., Gurmu, Y., Kuder, J. F., Im, K., Magnani, G., Oude Ophuis, T., Hamm, C., Špinar, J., Kiss, R. G., Van de Werf, F. J., Montalescot, G., Johanson, P., Braunwald, E., Sabatine, M. S., & Bonaca, M. P. (2021). Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Journal of the American Heart Association, 10(17), e020446. https://doi.org/10.1161/JAHA.120.020446
Bergmark, Brian A, et al. "Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial." Journal of the American Heart Association vol. 10,17 (2021): e020446. doi: https://doi.org/10.1161/JAHA.120.020446
Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, Špinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2021 Sep 07;10(17):e020446. doi: 10.1161/JAHA.120.020446. Epub 2021 Aug 21. PMID: 34423649.
Copy Download .nbib Format: NLM
The false illusion of coronary thrombus device-management.

Journal of thoracic disease

Lattuca B, Montalescot G.
PMID: 30631570
J Thorac Dis. 2018 Nov;10:S4117-S4121. doi: 10.21037/jtd.2018.10.25.

No abstract available.

Cite
Lattuca B, Montalescot G. The false illusion of coronary thrombus device-management. J Thorac Dis. 2018;10:S4117-S4121doi: 10.21037/jtd.2018.10.25.
Lattuca, B., & Montalescot, G. (2018). The false illusion of coronary thrombus device-management. Journal of thoracic disease, 10S4117-S4121. https://doi.org/10.21037/jtd.2018.10.25
Lattuca, Benoit, and Montalescot, Gilles. "The false illusion of coronary thrombus device-management." Journal of thoracic disease vol. 10 (2018): S4117-S4121. doi: https://doi.org/10.21037/jtd.2018.10.25
Lattuca B, Montalescot G. The false illusion of coronary thrombus device-management. J Thorac Dis. 2018 Nov;10:S4117-S4121. doi: 10.21037/jtd.2018.10.25. PMID: 30631570; PMCID: PMC6297490.
Copy Download .nbib Format: NLM
Non-ST-Segment Elevation Acute Coronary Syndrome: The Last Nail in the Coffin of Pre-Treatment.

Journal of the American College of Cardiology

Montalescot G.
PMID: 33213724
J Am Coll Cardiol. 2020 Nov 24;76(21):2460-2462. doi: 10.1016/j.jacc.2020.10.010.

No abstract available.

Cite
Montalescot G. Non-ST-Segment Elevation Acute Coronary Syndrome: The Last Nail in the Coffin of Pre-Treatment. J Am Coll Cardiol. 2020;76(21):2460-2462doi: 10.1016/j.jacc.2020.10.010.
Montalescot, G. (2020). Non-ST-Segment Elevation Acute Coronary Syndrome: The Last Nail in the Coffin of Pre-Treatment. Journal of the American College of Cardiology, 76(21), 2460-2462. https://doi.org/10.1016/j.jacc.2020.10.010
Montalescot, Gilles. "Non-ST-Segment Elevation Acute Coronary Syndrome: The Last Nail in the Coffin of Pre-Treatment." Journal of the American College of Cardiology vol. 76,21 (2020): 2460-2462. doi: https://doi.org/10.1016/j.jacc.2020.10.010
Montalescot G. Non-ST-Segment Elevation Acute Coronary Syndrome: The Last Nail in the Coffin of Pre-Treatment. J Am Coll Cardiol. 2020 Nov 24;76(21):2460-2462. doi: 10.1016/j.jacc.2020.10.010. PMID: 33213724.
Copy Download .nbib Format: NLM
The P2Y(12) receptor as a target of antithrombotic drugs.

Purinergic signalling

O'Connor S, Montalescot G, Collet JP.
PMID: 21710143
Purinergic Signal. 2011 Sep;7(3):325-32. doi: 10.1007/s11302-011-9241-z. Epub 2011 Jun 28.

No abstract available.

Cite
O'Connor S, Montalescot G, Collet JP. The P2Y(12) receptor as a target of antithrombotic drugs. Purinergic Signal. 2011;7(3):325-32doi: 10.1007/s11302-011-9241-z.
O'Connor, S., Montalescot, G., & Collet, J. P. (2011). The P2Y(12) receptor as a target of antithrombotic drugs. Purinergic signalling, 7(3), 325-32. https://doi.org/10.1007/s11302-011-9241-z
O'Connor, Stephen, et al. "The P2Y(12) receptor as a target of antithrombotic drugs." Purinergic signalling vol. 7,3 (2011): 325-32. doi: https://doi.org/10.1007/s11302-011-9241-z
O'Connor S, Montalescot G, Collet JP. The P2Y(12) receptor as a target of antithrombotic drugs. Purinergic Signal. 2011 Sep;7(3):325-32. doi: 10.1007/s11302-011-9241-z. Epub 2011 Jun 28. PMID: 21710143; PMCID: PMC3166993.
Copy Download .nbib Format: NLM
Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment.

TH open : companion journal to thrombosis and haemostasis

Bergmeijer TO, van Oevelen M, Janssen PWA, Godschalk TC, Lichtveld RA, Kelder JC, Voskuil M, Mosterd A, Montalescot G, Ten Berg JM.
PMID: 31249961
TH Open. 2018 Oct 11;2(4):e357-e368. doi: 10.1055/s-0038-1673389. eCollection 2018 Oct.

No abstract available.

Cite
Bergmeijer TO, van Oevelen M, Janssen PWA, et al. Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment. TH Open. 2018;2(4):e357-e368doi: 10.1055/s-0038-1673389.
Bergmeijer, T. O., van Oevelen, M., Janssen, P. W. A., Godschalk, T. C., Lichtveld, R. A., Kelder, J. C., Voskuil, M., Mosterd, A., Montalescot, G., & Ten Berg, J. M. (2018). Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment. TH open : companion journal to thrombosis and haemostasis, 2(4), e357-e368. https://doi.org/10.1055/s-0038-1673389
Bergmeijer, Thomas O, et al. "Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment." TH open : companion journal to thrombosis and haemostasis vol. 2,4 (2018): e357-e368. doi: https://doi.org/10.1055/s-0038-1673389
Bergmeijer TO, van Oevelen M, Janssen PWA, Godschalk TC, Lichtveld RA, Kelder JC, Voskuil M, Mosterd A, Montalescot G, Ten Berg JM. Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment. TH Open. 2018 Oct 11;2(4):e357-e368. doi: 10.1055/s-0038-1673389. eCollection 2018 Oct. PMID: 31249961; PMCID: PMC6524899.
Copy Download .nbib Format: NLM
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.

European heart journal. Cardiovascular pharmacotherapy

Ortega-Paz L, Galli M, Capodanno D, Franchi F, Rollini F, Bikdeli B, Mehran R, Montalescot G, Gibson CM, Lopes RD, Andreotti F, Angiolillo DJ.
PMID: 34519777
Eur Heart J Cardiovasc Pharmacother. 2021 Sep 14; doi: 10.1093/ehjcvp/pvab070. Epub 2021 Sep 14.

BACKGROUND: The clinical impact of different prophylactic anticoagulation regimens among hospitalized patients with COVID-19 remains unclear. We pooled evidence from available randomized controlled trials (RCTs) to provide insights on this topic.METHODS AND RESULTS: We searched for RCTs comparing treatment...

Cite
Ortega-Paz L, Galli M, Capodanno D, et al. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021;doi: 10.1093/ehjcvp/pvab070.
Ortega-Paz, L., Galli, M., Capodanno, D., Franchi, F., Rollini, F., Bikdeli, B., Mehran, R., Montalescot, G., Gibson, C. M., Lopes, R. D., Andreotti, F., & Angiolillo, D. J. (2021). Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. European heart journal. Cardiovascular pharmacotherapy, . https://doi.org/10.1093/ehjcvp/pvab070
Ortega-Paz, Luis, et al. "Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials." European heart journal. Cardiovascular pharmacotherapy vol. (2021). doi: https://doi.org/10.1093/ehjcvp/pvab070
Ortega-Paz L, Galli M, Capodanno D, Franchi F, Rollini F, Bikdeli B, Mehran R, Montalescot G, Gibson CM, Lopes RD, Andreotti F, Angiolillo DJ. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021 Sep 14; doi: 10.1093/ehjcvp/pvab070. Epub 2021 Sep 14. PMID: 34519777; PMCID: PMC8499924.
Copy Download .nbib Format: NLM
Does severe renal insufficiency increase the risk of bleeding after administration of low-molecular-weight heparin?.

Nature clinical practice. Nephrology

Collet JP, Montalescot G.
PMID: 17066050
Nat Clin Pract Nephrol. 2006 Nov;2(11):616-7. doi: 10.1038/ncpneph0323.

No abstract available.

Cite
Collet JP, Montalescot G. Does severe renal insufficiency increase the risk of bleeding after administration of low-molecular-weight heparin?. Nat Clin Pract Nephrol. 2006;2(11):616-7doi: 10.1038/ncpneph0323.
Collet, J. P., & Montalescot, G. (2006). Does severe renal insufficiency increase the risk of bleeding after administration of low-molecular-weight heparin?. Nature clinical practice. Nephrology, 2(11), 616-7. https://doi.org/10.1038/ncpneph0323
Collet, Jean-Philippe, and Montalescot, Gilles. "Does severe renal insufficiency increase the risk of bleeding after administration of low-molecular-weight heparin?." Nature clinical practice. Nephrology vol. 2,11 (2006): 616-7. doi: https://doi.org/10.1038/ncpneph0323
Collet JP, Montalescot G. Does severe renal insufficiency increase the risk of bleeding after administration of low-molecular-weight heparin?. Nat Clin Pract Nephrol. 2006 Nov;2(11):616-7. doi: 10.1038/ncpneph0323. PMID: 17066050.
Copy Download .nbib Format: NLM
Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease.

Journal of health psychology

Montalescot L, Speyer E, Legrand K, Ayav C, Combe C, Stengel B, Untas A.
PMID: 32772863
J Health Psychol. 2022 Jan;27(1):166-175. doi: 10.1177/1359105320949921. Epub 2020 Aug 10.

The Family Relationship Index (FRI) measures family cohesion, expressiveness and conflict. This study aimed to investigate its reliability and validity in patients with chronic kidney disease (CKD). Confirmatory factor analysis was performed on 1657 patients and on subgroups according...

Cite
Montalescot L, Speyer E, Legrand K, et al. Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease. J Health Psychol. 2020;27(1):166-175doi: 10.1177/1359105320949921.
Montalescot, L., Speyer, E., Legrand, K., Ayav, C., Combe, C., Stengel, B., & Untas, A. (2022). Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease. Journal of health psychology, 27(1), 166-175. https://doi.org/10.1177/1359105320949921
Montalescot, Lucile, et al. "Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease." Journal of health psychology vol. 27,1 (2022): 166-175. doi: https://doi.org/10.1177/1359105320949921
Montalescot L, Speyer E, Legrand K, Ayav C, Combe C, Stengel B, Untas A. Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease. J Health Psychol. 2022 Jan;27(1):166-175. doi: 10.1177/1359105320949921. Epub 2020 Aug 10. PMID: 32772863.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 44 entries